Krina K. Patel, MD, MSc

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss questions ongoing research with CAR T-cell therapy in multiple myeloma aims to address.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail key CAR T-cell therapy data in multiple myeloma from ASH 2025.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss potential targets for novel CAR T-cell therapies in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss findings from the iMMagine-1 of anito-cel in relapsed/refractory multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss the investigational CAR T-cell therapy anito-cel in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, explain the role of bridging therapy alongside CAR T-cell therapy in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail the drive beyond additional CAR T-cell therapy research in multiple myeloma.

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss treatment approaches in fourth- and later-line multiple myeloma.

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.